As filed with the Securities and Exchange Commission on January 28, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
| | |
Delaware | | 27-0838048 |
(State or Other Jurisdiction of | | (I.R.S. Employer |
Incorporation or Organization) | | Identification No.) |
1700 Owens Street, Suite 205
San Francisco, California 94158
(Address of Principal Executive Offices) (Zip Code)
2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan
(Full Title of the Plans)
Arthur T. Sands
President and Chief Executive Officer
Nurix Therapeutics, Inc.
1700 Owens Street, Suite 205
San Francisco, California 94158
(Name and Address of Agent for Service)
(415) 660-5320
(Telephone Number, including area code, of agent for service)
Please send copies of all communications to:
| | |
Michael A. Brown, Esq. Robert A. Freedman, Esq. Amanda L. Rose, Esq. Fenwick & West LLP 555 California Street, 12th Floor San Francisco, California 94104 (415) 875-2300 | | Christine Ring, Esq. General Counsel and Secretary Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, California 94158 (415) 660-5320 |
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☒ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☐ | | Smaller reporting company | | ☐ |
| | | |
| | | | Emerging growth company | | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| | | | | | | | |
|
Title of Securities To Be Registered | | Amount to Be Registered(1) | | Proposed Maximum Offering Price Per Share | | Proposed Maximum Aggregate Offering Price | | Amount of Registration Fee |
Common Stock, $0.001 par value per share, reserved for future issuance pursuant to: | | | | | | | | |
—2020 Equity Incentive Plan | | 1,787,545(2) | | $17.94(3) | | $32,068,558 | | $2,973 |
—2020 Employee Stock Purchase Plan | | 446,643(4) | | $15.25(5) | | $6,811,306 | | $632 |
TOTAL | | 2,234,188 | | N/A | | $38,879,864 | | $3,605 |
|
|
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the Registrant’s 2020 Equity Incentive Plan (the “2020 EIP”) and 2020 Employee Stock Purchase Plan (“2020 ESPP”) by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the Registrant’s receipt of consideration that increases the number of the outstanding shares of the Registrant’s common stock. |
(2) | Represents 1,787,545 additional shares to be registered and available for grant under the 2020 EIP resulting from: (i) 1,786,574 additional shares of the Registrant’s common stock available for issuance pursuant to the annual 4% automatic increase in the number of authorized shares available for issuance under the 2020 EIP and (ii) 971 additional shares of the Registrant’s common stock available for issuance under the 2020 EIP as a result of the repurchase of unvested and forfeited shares of the Registrant’s common stock acquired upon the exercise of stock options that were previously granted and early exercised under the Registrant’s 2012 Equity Incentive Plan (the “2012 EIP”) pursuant to the terms of the 2020 EIP. |
(3) | Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $17.94 was computed by averaging the high and low prices of a share of Registrant’s common stock as reported on The Nasdaq Global Market on January 27, 2022. |
(4) | Represents additional shares of the Registrant’s common stock to be registered and available for grant under the 2020 ESPP resulting from the annual 1% automatic increase in the number of authorized shares available for issuance under the 2020 ESPP. |
(5) | Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act solely for the purpose of calculating the registration fee. The proposed maximum offering price per share of $15.25 was computed by averaging the high and low prices of a share of Registrant’s common stock as reported on The Nasdaq Global Market on January 27, 2022, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2020 ESPP. |